Company Website:
http://www.glancylaw.com
LOS ANGELES -- (Business Wire)
Glancy
Binkow & Goldberg LLP reminds investors of Vertex
Pharmaceuticals Incorporated (“Vertex” or the “Company”)
(NASDAQ:VRTX) that all purchasers of Vertex common stock between May 7,
2012 and May 29, 2012, inclusive (the “Class Period”) have until July
28, 2014, to file a motion to be appointed as lead plaintiff in the
shareholder lawsuit.
Vertexis engaged in discovering, developing, manufacturing and
commercializing small molecule drugs for patients with serious diseases.
The Company markets Kalydeco in the United States and European Union as
a treatment for patients aged six years and older with a rare form of
cystic fibrosis. The Complaint alleges that the Company issued false and
misleading public statements concerning Vertex’s products VX-809 and
Kalydeco.
On May 29, 2012, the Company issued a correction of the interim analysis
of the Phase 2 Combination Study of VX-809 and Kalydeco, stating that
the correction was due to a “misinterpretation” between Vertex and a
third-party statistical analysis vendor over the study data. Following
this news, the Company’s stock price plummeted from its previous closing
price of $64.85 on May 25, 2012, to close at $57.80 per share on May 29,
2012.
If you are a member of the Class described above, you may move the Court
no later than July 28, 2014, to serve as lead plaintiff; however, you
must meet certain legal requirements. To be a member of the Class, you
need not take any action at this time; you may retain counsel of your
choice or take no action and remain an absent member of the Class. If
you wish to learn
more about this action or have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Lesley Portnoy, Esquire, of Glancy Binkow & Goldberg LLP,
1925 Century Park East, Suite 2100, Los Angeles, California 90067, at
(646) 539-8980, by e-mail to shareholders@glancylaw.com,
or visit our website at http://www.glancylaw.com.
If you inquire by email, please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Contacts:
Glancy Binkow & Goldberg LLP, Los Angeles, CA
Lesley Portnoy,
646-539-8980
shareholders@glancylaw.com
www.glancylaw.com
Source: Glancy Binkow & Goldberg LLP
© 2024 Canjex Publishing Ltd. All rights reserved.